Nifty
:
25285.35
Sensex
:
82500.82
103.55 (0.41%)
328.72 (0.40%)
Nifty
Sensex
:
:
25285.35
82500.82
103.55 (0.41%)
328.72 (0.40%)

Cohance Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
48/99

BSE: 543064 | NSE: COHANCE

NSE BSE
904.75
10-Oct-2025
  • Open
  • High
  • Low
  • Previous Close
  •  881.5
  •  907.65
  •  875.6
  •  881.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  496440
  •  446859100.2
  •  1360
  •  856

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 34,614.67
  • 135.22
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 34,604.13
  • N/A
  • 19.91

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 66.41%
  • 7.41%
  • 6.40%
  • FII
  • DII
  • Others
  • 7.23%
  • 11.18%
  • 1.37%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 3.47
  • -3.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -3.27
  • -8.16

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -2.79
  • -13.32

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 35.33
  • 44.63

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 10.89
  • 11.58

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 37.58
  • 45.78

Earnings Forecasts:

(Updated: 11-10-2025)
Description
2024
2025
2026
2027
Adj EPS
10.52
15.52
21.24
27.15
P/E Ratio
86.00
58.30
42.60
33.32
Revenue
1172.28
3102.3
3803.4
4630.9
EBITDA
375.2
918.67
1220.64
1505.26
Net Income
267.87
574.53
799.27
1018.97
ROA
10.13
17.52
20.05
27.69
P/B Ratio
13.58
9.18
7.66
6.32
ROE
14.3
15.18
18.45
20.13
FCFF
129.05
231.17
416.93
1605.43
FCFF Yield
0.39
0.69
1.25
4.8
Net Debt
-1.34
-141.66
-434.93
-1152.27
BVPS
66.64
98.53
118.08
143.23

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
549.31
488.08
12.55%
402.02
252.93
58.95%
307.15
219.82
39.73%
257.72
231.05
11.54%
Expenses
437.30
362.98
20.47%
328.46
179.59
82.89%
189.45
153.74
23.23%
153.71
132.41
16.09%
EBITDA
112.01
125.10
-10.46%
73.56
73.34
0.30%
117.70
66.08
78.12%
104.01
98.64
5.44%
EBIDTM
20.39%
25.63%
18.30%
29.00%
38.32%
30.06%
40.36%
42.69%
Other Income
14.17
19.41
-27.00%
10.57
17.06
-38.04%
15.71
14.34
9.55%
14.12
19.84
-28.83%
Interest
10.18
10.20
-0.20%
5.75
2.30
150.00%
3.33
2.16
54.17%
1.67
1.14
46.49%
Depreciation
45.14
31.28
44.31%
26.78
17.25
55.25%
20.35
12.79
59.11%
16.96
11.95
41.92%
PBT
62.76
103.03
-39.09%
51.60
70.85
-27.17%
109.73
65.47
67.60%
99.50
105.39
-5.59%
Tax
16.36
27.66
-40.85%
12.87
17.48
-26.37%
26.44
18.72
41.24%
17.52
25.84
-32.20%
PAT
46.40
75.37
-38.44%
38.73
53.37
-27.43%
83.29
46.75
78.16%
81.98
79.55
3.05%
PATM
8.45%
15.44%
9.63%
21.10%
27.12%
21.27%
31.81%
34.43%
EPS
1.28
2.96
-56.76%
1.65
2.10
-21.43%
3.26
1.84
77.17%
3.23
3.12
3.53%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Net Sales
1,516.20
1,197.58
1,051.35
1,340.33
1,320.22
1,009.72
833.79
377.83
Net Sales Growth
27.21%
13.91%
-21.56%
1.52%
30.75%
21.10%
120.68%
 
Cost Of Goods Sold
389.83
300.73
311.86
402.97
394.05
297.56
225.32
101.46
Gross Profit
1,126.37
896.85
739.49
937.36
926.17
712.16
608.47
276.37
GP Margin
74.29%
74.89%
70.34%
69.94%
70.15%
70.53%
72.98%
73.15%
Total Expenditure
1,108.92
822.38
645.54
766.17
738.50
566.72
449.03
206.28
Power & Fuel Cost
-
47.29
48.30
73.93
59.55
44.20
38.23
18.06
% Of Sales
-
3.95%
4.59%
5.52%
4.51%
4.38%
4.59%
4.78%
Employee Cost
-
249.56
135.23
118.25
100.48
76.23
65.10
29.63
% Of Sales
-
20.84%
12.86%
8.82%
7.61%
7.55%
7.81%
7.84%
Manufacturing Exp.
-
102.96
88.37
109.62
129.24
105.31
83.89
35.11
% Of Sales
-
8.60%
8.41%
8.18%
9.79%
10.43%
10.06%
9.29%
General & Admin Exp.
-
45.34
27.11
33.87
28.99
27.73
25.97
12.62
% Of Sales
-
3.79%
2.58%
2.53%
2.20%
2.75%
3.11%
3.34%
Selling & Distn. Exp.
-
14.32
10.46
17.64
19.80
10.53
9.43
6.72
% Of Sales
-
1.20%
0.99%
1.32%
1.50%
1.04%
1.13%
1.78%
Miscellaneous Exp.
-
62.18
24.21
9.90
6.37
5.16
1.08
2.69
% Of Sales
-
5.19%
2.30%
0.74%
0.48%
0.51%
0.13%
0.71%
EBITDA
407.28
375.20
405.81
574.16
581.72
443.00
384.76
171.55
EBITDA Margin
26.86%
31.33%
38.60%
42.84%
44.06%
43.87%
46.15%
45.40%
Other Income
54.57
58.56
61.91
46.36
92.38
14.24
18.12
0.60
Interest
20.93
12.35
7.45
12.81
8.53
11.67
23.07
2.79
Depreciation
109.23
77.49
54.60
47.99
39.10
31.64
23.51
11.50
PBT
323.59
343.92
405.67
559.73
626.48
413.94
356.30
157.87
Tax
73.19
79.15
105.39
148.44
213.78
105.33
87.51
48.59
Tax Rate
22.62%
23.01%
25.98%
26.52%
34.12%
25.45%
24.56%
30.78%
PAT
250.40
267.87
300.28
411.29
453.80
308.61
268.79
109.27
PAT before Minority Interest
255.98
264.77
300.28
411.29
453.80
308.61
268.79
109.27
Minority Interest
5.58
3.10
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
16.51%
22.37%
28.56%
30.69%
34.37%
30.56%
32.24%
28.92%
PAT Growth
-1.82%
-10.79%
-26.99%
-9.37%
47.05%
14.81%
145.99%
 
EPS
6.54
7.00
7.85
10.75
11.86
8.07
7.03
2.86

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Shareholder's Funds
1,696.58
2,050.67
1,735.18
1,527.18
1,180.81
844.76
590.29
Share Capital
25.46
25.46
25.46
25.46
25.46
12.73
0.00
Total Reserves
1,654.23
2,023.24
1,709.73
1,501.72
1,155.35
832.03
577.56
Non-Current Liabilities
825.37
86.03
71.79
92.11
73.91
127.68
35.12
Secured Loans
6.24
0.00
4.56
28.44
35.59
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
91.25
0.00
Long Term Provisions
0.26
0.00
8.30
8.89
6.65
8.31
5.95
Current Liabilities
365.19
117.40
303.09
347.52
321.51
319.85
190.67
Trade Payables
80.21
42.35
70.09
105.90
82.93
71.06
53.57
Other Current Liabilities
196.01
21.23
19.84
29.54
28.57
27.51
19.47
Short Term Borrowings
70.00
38.58
64.60
67.13
105.64
94.04
82.79
Short Term Provisions
18.97
15.24
148.56
144.94
104.36
127.24
34.83
Total Liabilities
3,031.20
2,254.10
2,110.06
1,966.81
1,576.23
1,292.29
816.08
Net Block
1,713.42
669.62
663.33
534.19
441.16
356.74
270.90
Gross Block
2,045.63
929.16
875.60
693.81
569.62
456.66
347.41
Accumulated Depreciation
332.21
259.54
212.27
159.62
128.46
99.91
76.51
Non Current Assets
2,142.61
1,000.89
954.70
701.66
909.68
781.17
393.28
Capital Work in Progress
255.61
179.08
165.09
29.99
96.32
101.71
111.07
Non Current Investment
144.95
130.58
117.10
117.10
361.19
307.46
0.07
Long Term Loans & Adv.
24.05
21.61
9.19
13.07
10.85
15.06
11.02
Other Non Current Assets
4.58
0.00
0.00
7.30
0.16
0.20
0.22
Current Assets
853.28
1,253.21
1,155.37
1,265.16
666.54
511.12
422.80
Current Investments
191.74
773.90
418.94
481.22
180.59
30.67
7.06
Inventories
166.57
231.20
312.81
283.42
201.08
174.87
157.10
Sundry Debtors
284.44
133.66
110.94
236.37
102.38
117.20
147.50
Cash & Bank
88.67
50.50
68.01
47.31
9.65
14.07
12.90
Other Current Assets
121.86
11.90
11.46
9.15
172.83
174.30
98.24
Short Term Loans & Adv.
106.60
52.05
233.21
207.69
116.80
134.56
37.32
Net Current Assets
488.09
1,135.81
852.28
917.64
345.04
191.27
232.13
Total Assets
2,995.89
2,254.10
2,110.07
1,966.82
1,576.22
1,292.29
816.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Cash From Operating Activity
288.16
384.77
457.20
330.00
382.55
406.92
50.40
PBT
343.92
405.67
559.73
667.59
467.67
404.51
157.87
Adjustment
59.82
17.14
37.46
40.63
36.48
34.60
13.93
Changes in Working Capital
-32.14
71.91
5.77
-193.97
-12.17
54.21
-88.33
Cash after chg. in Working capital
371.60
494.72
602.96
514.26
491.98
493.33
83.47
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-83.44
-109.95
-145.76
-184.26
-109.44
-86.41
-33.06
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-255.30
-362.35
-195.01
-136.14
-311.40
-413.45
-65.48
Net Fixed Assets
-142.57
-230.17
-154.01
-57.86
-107.57
-99.89
Net Investments
-223.63
-182.51
-110.17
-173.65
-149.92
-269.19
Others
110.90
50.33
69.17
95.37
-53.91
-44.37
Cash from Financing Activity
3.32
-39.99
-241.95
-156.48
-75.66
7.32
25.98
Net Cash Inflow / Outflow
36.18
-17.57
20.24
37.38
-4.51
0.79
10.90
Opening Cash & Equivalents
47.23
64.80
44.56
7.18
11.70
10.90
0.00
Closing Cash & Equivalent
85.40
47.23
64.80
44.56
7.18
11.70
10.90

Financial Ratios

Standalone /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Book Value (Rs.)
65.97
80.47
68.16
59.99
46.39
33.18
0.00
ROA
10.02%
13.76%
20.18%
25.62%
21.52%
25.50%
13.39%
ROE
14.20%
15.87%
25.21%
33.52%
30.47%
37.80%
18.92%
ROCE
18.44%
21.22%
33.41%
45.92%
36.19%
44.55%
23.87%
Fixed Asset Turnover
0.81
1.17
1.71
2.09
1.97
2.07
1.09
Receivable days
63.71
42.46
47.25
46.80
39.69
57.94
142.49
Inventory Days
60.62
94.43
81.11
66.93
67.95
72.66
151.76
Payable days
74.38
65.80
79.70
87.45
94.44
49.88
86.75
Cash Conversion Cycle
49.95
71.09
48.66
26.27
13.19
80.72
207.50
Total Debt/Equity
0.05
0.02
0.04
0.06
0.12
0.22
0.14
Interest Cover
28.85
55.45
44.69
79.29
36.48
16.45
57.60

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020

News Update:


  • USFDA completes cGMP audit at Cohance Lifesciences’ Andhra Pradesh facility
    12th Sep 2025, 14:23 PM

    The inspection was conducted from September 8, 2025 to September 11, 2025 and concluded with zero Form 483 observations

    Read More
  • USFDA completes GMP inspection at Cohance Lifesciences’ Hyderabad facility
    14th Aug 2025, 10:30 AM

    Following the inspection, the Company has received a Form 483 from the USFDA with 06 observations

    Read More
  • Cohance Lifesciences - Quarterly Results
    13th Aug 2025, 17:14 PM

    Read More
  • Cohance Lifesciences to invest $10 million to expand cGMP bioconjugation capabilities at U.S based subsidiary
    12th Aug 2025, 17:45 PM

    NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.